Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -68.74% is 88% above its 5-year average of -586.69%, near the high end of its 5-year range (-1760.52%–-68.74%).
84.88% above its 12-month average of -454.56%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -48.36%.
RETURN ON ASSETS (ROA)
-68.74%
RETURN ON ASSETS (ROA) AVG TTM
-454.56%
RETURN ON ASSETS (ROA) AVG 3Y
-368.82%
RETURN ON ASSETS (ROA) AVG 5Y
-586.69%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+84.88%
CURRENT VS 3Y AVG
+81.36%
CURRENT VS 5Y AVG
+88.28%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-113.21%
vs the sector median at left
NRx Pharmaceuticals, Inc.
Market Cap
$127.29M
Return on Assets (ROA)
-68.74%
TTM Avg
-454.56%
3Y Avg
-368.82%
5Y Avg
-586.69%
Market Cap
$127.21M
Return on Assets (ROA)
-161.55%
TTM Avg
-68.10%
3Y Avg
-58.95%
5Y Avg
-64.88%
Market Cap
$126.43M
Return on Assets (ROA)
-87.44%
TTM Avg
-86.57%
3Y Avg
-87.06%
5Y Avg
-85.09%
Market Cap
$124.82M
Return on Assets (ROA)
-96.49%
TTM Avg
-109.25%
3Y Avg
-126.41%
5Y Avg
-190.40%
Market Cap
$130.16M
Return on Assets (ROA)
-6.07%
TTM Avg
-5.08%
3Y Avg
-4.92%
5Y Avg
-1.70%
Market Cap
$124.26M
Return on Assets (ROA)
-62.84%
TTM Avg
-62.29%
3Y Avg
-62.24%
5Y Avg
-56.44%
Market Cap
$131.55M
Return on Assets (ROA)
-35.50%
TTM Avg
-18.07%
3Y Avg
-62.20%
5Y Avg
-134.72%
Market Cap
$131.16M
Return on Assets (ROA)
-73.85%
TTM Avg
-21.75%
3Y Avg
-19.65%
5Y Avg
-19.48%
Market Cap
$121.25M
Return on Assets (ROA)
-1.70%
TTM Avg
-35.34%
3Y Avg
-51.03%
5Y Avg
-36.99%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NRx Pharmaceuticals, Inc. (NRXP) | $127.29M | -68.74% | -454.56% | -368.82% | -586.69% |
| Pyxis Oncology, Inc. (PYXS)vs › | $127.21M | -161.55% | -68.10% | -58.95% | -64.88% |
| Entera Bio Ltd. (ENTX)vs › | $126.43M | -87.44% | -86.57% | -87.06% | -85.09% |
| TuHURA Biosciences, Inc. (HURA)vs › | $124.82M | -96.49% | -109.25% | -126.41% | -190.40% |
| AirSculpt Technologies, Inc. (AIRS)vs › | $130.16M | -6.07% | -5.08% | -4.92% | -1.70% |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $124.26M | -62.84% | -62.29% | -62.24% | -56.44% |
| LifeMD, Inc. (LFMD)vs › | $131.55M | -35.50% | -18.07% | -62.20% | -134.72% |
| Health Catalyst, Inc. (HCAT)vs › | $131.16M | -73.85% | -21.75% | -19.65% | -19.48% |
| enGene Holdings Inc. (ENGN)vs › | $121.25M | -1.70% | -35.34% | -51.03% | -36.99% |
| Seer, Inc. (SEER)vs › | $121.23M | -26.48% | -24.24% | -21.83% | -17.99% |
ROA
-68.7%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -220.92% |
| 2024-12-31 | -688.20% |
| 2023-12-31 | -412.17% |
| 2022-12-31 | -153.99% |
| 2021-12-31 | -284.34% |
| 2020-12-31 | -1760.52% |
| 2019-12-31 | 1.27% |
| 2018-12-31 | 0.09% |
| 2017-12-31 | -0.15% |
